Full Endoscopic Interlaminar Approach for Paracentral L5-S1 Disc Herniation
April 14th, 2023
1.4K views
Here, we present a protocol to describe the full endoscopic interlaminar approach (FEILA) technique, including every cutoff step required to reach technical proficiency. FEILA is a surgery with a relatively steep learning adaptation. Despite this, any surgeon capable of microdiscectomy can perform FEILA with enough practice and suitable patient selection.
Overview
This article presents a protocol for the full endoscopic interlaminar approach (FEILA) technique, detailing each step necessary to achieve technical proficiency. Although FEILA has a steep learning curve, it is accessible to any surgeon skilled in microdiscectomy with adequate practice and appropriate patient selection.
Key Study Components
Area of Science
- Neurosurgery
- Endoscopic techniques
- Microdiscectomy
Background
- FEILA is a novel surgical approach.
- It requires specific skills and training.
- Understanding the protocol is essential for successful implementation.
- Surgeons must adapt to the technique's demands.
Purpose of Study
- To provide a comprehensive guide to the FEILA technique.
- To enhance surgical proficiency among practitioners.
- To facilitate better patient outcomes through improved surgical methods.
Methods Used
- Detailed protocol description.
- Step-by-step guidance for surgeons.
- Assessment of technical proficiency.
- Patient selection criteria.
Main Results
- FEILA can be performed by trained surgeons.
- Practice leads to improved surgical outcomes.
- Clear guidelines enhance learning and adaptation.
- Successful implementation depends on patient selection.
Conclusions
- FEILA is a viable surgical option for microdiscectomy.
- Surgeons can achieve proficiency with practice.
- Proper training and patient selection are crucial for success.
Frequently Asked Questions
What is the FEILA technique?
FEILA stands for Full Endoscopic Interlaminar Approach, a surgical method for addressing spinal issues.
Who can perform the FEILA technique?
Any surgeon skilled in microdiscectomy can learn to perform FEILA with practice.
What are the key components of the FEILA protocol?
The protocol includes detailed steps, technical proficiency assessment, and patient selection criteria.
How does one achieve proficiency in FEILA?
Proficiency is achieved through practice and understanding of the technique's requirements.
What are the expected outcomes of using FEILA?
Expected outcomes include improved surgical results and enhanced patient recovery.
Is FEILA suitable for all patients?
Patient selection is critical; not all patients may be suitable for this technique.
Executive Industry Relevance
Standardization of minimally invasive surgical protocols like the full endoscopic interlaminar approach (FEILA) is critical for translational research and device development in spine therapeutics. FEILA's reproducibility and reduced tissue trauma offer a platform for evaluating novel biomaterials, surgical tools, and perioperative interventions in preclinical and early clinical settings. Its adoption impacts the reliability of comparative studies and supports risk-adjusted advancement of new spinal technologies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables controlled evaluation of device-tissue interactions in a standardized surgical context.
- Supports mechanistic de-risking for biomaterial and implant candidates targeting spinal repair.
- Facilitates reproducible assessment of perioperative pharmacological interventions.
Screening & Assay Development
- Provides a validated surgical model for preclinical screening of wound healing and anti-inflammatory agents.
- Enables quantitative measurement of tissue response and complication rates post-intervention.
- Supports assay standardization for device and drug combination studies.
Translational & Preclinical Research
- Aligns with disease-relevant models for lumbar disc herniation and repair.
- Enables continuity from preclinical device testing to early clinical feasibility studies.
- Supports risk-adjusted go/no-go decisions for new spinal therapeutics.
Pipeline & Workflow Integration
FEILA serves as a reproducible surgical platform bridging preclinical device evaluation and early clinical research in spinal disorders.
- Discovery Biology: Supports hypothesis testing for device efficacy and tissue compatibility.
- Screening: Enables standardized assessment of post-surgical outcomes and complication rates.
- Analytics: Provides quantitative endpoints for comparing intervention groups.
- Translational Research: Facilitates alignment with clinical models of lumbar disc herniation.
- Enterprise Reuse: Offers a reusable protocol for iterative device and drug development cycles.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in device and therapeutic candidate performance.
- Operational Value: Enhances reproducibility and standardization across research teams.
- Strategic Value: Reduces late-stage biological risk and supports efficient portfolio triage.
- Portfolio Impact: Informs risk-adjusted prioritization of spinal therapeutic programs.
Implementation Considerations
- Requires specialized surgical expertise and training in endoscopic techniques.
- Demands access to endoscopic instrumentation and imaging infrastructure.
- Necessitates protocol standardization for cross-site reproducibility.
- May require adaptation for use in different preclinical or clinical model systems.
- Learning curve and technical proficiency thresholds must be addressed for consistent outcomes.
Biopharma FAQs
Why does null hypothesis testing matter for FEILA-based target validation?
Null hypothesis testing in FEILA protocols enables objective evaluation of device or therapeutic effects versus standard care, supporting robust target validation and reducing bias in early-stage research.
How does independent variable isolation fit FEILA in the discovery pipeline?
Isolating variables such as device type or perioperative agent within the FEILA model allows clear attribution of observed outcomes, strengthening mechanistic insights and informing downstream development decisions.
What do quantitative dependent variable measurements enable in FEILA studies?
Quantitative measurements of outcomes like complication rates and tissue healing provide actionable data for comparing interventions, supporting predictive confidence and portfolio advancement.
Why are replication requirements critical for FEILA cross-functional collaboration?
Replication ensures that FEILA-based findings are reproducible across teams and sites, enabling reliable cross-functional data integration and collaborative decision-making in R&D programs.
What statistical analysis capabilities are required before FEILA implementation?
Robust statistical analysis is needed to interpret FEILA study data, assess significance of outcomes, and guide risk-adjusted go/no-go decisions in device and therapeutic development pipelines.
